Want to see DOCS full AI Analyst Report?
DOCS Stock Chart & Stats
$24.74
-$0.03(-0.15%)
At close: 4:00 PM EDT
$24.74
-$0.03(-0.15%)
Day’s Range― - ―
52-Week Range$17.15 - $71.37
Previous Close$20.42
Volume2.18M
Average Volume (3M)3.04M
Market Cap
$5.61B
Enterprise Value$3.29B
Total Cash (Recent Filing)$687.79M
Total Debt (Recent Filing)$9.67M
Price to Earnings (P/E)37.5
Beta1.75
Next Earnings
Nov 05, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.89
Shares Outstanding127,349,365
10 Day Avg. Volume3,376,530
30 Day Avg. Volume3,044,780
Financial Highlights & Ratios
PEG Ratio-1.89
Price to Book (P/B)4.58
Price to Sales (P/S)6.76
P/FCF Ratio13.72
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue5.01
Enterprise Value/Gross Profit5.69
Enterprise Value/Ebitda13.58
Forecast
1Y Price Target
$31.20Price Target Upside26.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)1.35
Revenue Forecast (FY)$677.61M
Bulls Say, Bears Say
Bulls Say
Scalable Profitability And Cash GenerationDoximity combines high gross and operating margins with free cash flow that closely tracks earnings, indicating a scalable software and platform model. This cash-generative profile can support product investment, commercial expansion, and shareholder returns while preserving financial resilience.
Minimal Leverage And Strong LiquidityA debt-free balance sheet and substantial liquidity give Doximity flexibility to fund AI development, pursue strategic opportunities, and continue repurchases without relying heavily on external financing. Low leverage also reduces exposure to interest costs and refinancing pressure.
Growing Enterprise AI Adoption And Content QualityIntegrating UpToDate’s trusted clinical content can strengthen Ask’s usefulness and credibility for clinicians and health systems. Broader evidence-based coverage may improve enterprise adoption, reinforce Doximity’s workflow ecosystem, and create a more defensible AI product position.
Bears Say
Revenue Growth Is DeceleratingThe reduced growth outlook shows that Doximity is moving from earlier expansion rates toward a more moderate trajectory. Slower revenue growth can limit operating leverage, increase dependence on successful AI monetization, and make sustained earnings expansion more challenging.
AI Investment Is Pressuring Gross MarginsAI compute costs are directly reducing gross margin and are expected to remain a factor as adoption expands. If monetization does not scale alongside usage, the investment cycle could dilute Doximity’s historically strong profitability and reduce cash conversion.
Tight Pharma Budgets Constrain DemandDoximity relies substantially on life sciences customers, so restrained pharma budgets can slow campaign spending and adoption of newer AI offerings. This creates a durable demand risk until customers allocate more funding to innovation and digital clinician engagement.
Doximity News
DOCS FAQ
What was Doximity’s price range in the past 12 months?
Doximity lowest stock price was $17.15 and its highest was $71.37 in the past 12 months.
What is Doximity’s market cap?
Doximity’s market cap is $5.61B.
When is Doximity’s upcoming earnings report date?
Doximity’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Doximity’s earnings last quarter?
Doximity released its earnings results on Aug 06, 2026. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.303 by -$0.013.
Is Doximity overvalued?
According to Wall Street analysts Doximity’s price is currently Undervalued.
Does Doximity pay dividends?
Doximity does not currently pay dividends.
What is Doximity’s EPS estimate?
Doximity’s EPS estimate is 0.35.
How many shares outstanding does Doximity have?
Doximity has 127,349,365 shares outstanding.
What happened to Doximity’s price movement after its last earnings report?
Doximity reported an EPS of $0.29 in its last earnings report, missing expectations of $0.303. Following the earnings report the stock price went up 32.623%.
Which hedge fund is a major shareholder of Doximity?
Currently, no hedge funds are holding shares in DOCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Doximity Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.20 (26.11% Upside)
$31.20 (26.11% Upside)
Blogger Sentiment
Neutral
DOCS Sentiment 55%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 202.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.95%
12-Months-Change
Fundamentals
Return on Equity
16.95%
Trailing 12-Months
Asset Growth
-10.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Doximity
Doximity, Inc. provides a digital platform, hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. This platform delivers a suite of specialized tools, empowering its members to connect with peers, streamline patient treatment, conduct remote consultations, access current medical information and research, and advance their professional careers. Its primary clientele consists of pharmaceutical companies and healthcare organizations. Established in 2010, the entity initially operated as 3MD Communications, Inc. before rebranding to Doximity, Inc. in June of that year. The company's corporate headquarters are situated in San Francisco, California.
DOCS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call combined strong financial and operational positives — revenue and adjusted EBITDA beats, raised full‑year guidance, robust cash balance, aggressive share repurchases, independent validation of Doximity Ask, rapid clinician adoption and meaningful enterprise wins — with managed near‑term tradeoffs driven by deliberate AI investment. Short‑term impacts include lower gross margin from compute spend, higher OpEx and a cautious Q2 growth comp, but management positioned these as intentional investments to capture a large long‑term AI opportunity while preserving high margins. Overall the positives (beat, guidance raise, product validation, adoption and balance sheet strength) outweigh the near‑term headwinds tied to investment cadence and timing of AI monetization.View all DOCS earnings summariesDOCS Revenue Breakdown
93.00% Subscription
7.00% Other
DOCS Stock 12 Month Forecast
Average Price Target
$31.20
▲(26.11% Upside)
Technical Analysis
Ownership Overview
3.61% Insiders
26.74% Mutual Funds
1.45% Other Institutional Investors
46.02% Public Companies and
Individual Investors